WO1999049788A1 - Ablation system - Google Patents

Ablation system Download PDF

Info

Publication number
WO1999049788A1
WO1999049788A1 PCT/US1999/006974 US9906974W WO9949788A1 WO 1999049788 A1 WO1999049788 A1 WO 1999049788A1 US 9906974 W US9906974 W US 9906974W WO 9949788 A1 WO9949788 A1 WO 9949788A1
Authority
WO
WIPO (PCT)
Prior art keywords
transducer
adjacent
treatment region
orientation
catheter
Prior art date
Application number
PCT/US1999/006974
Other languages
French (fr)
Other versions
WO1999049788A9 (en
Inventor
Francis J. Fry
Michael H. Phillips
Narendra T. Sanghvi
Original Assignee
Focus Surgery, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Focus Surgery, Inc. filed Critical Focus Surgery, Inc.
Priority to US09/647,317 priority Critical patent/US6685640B1/en
Publication of WO1999049788A1 publication Critical patent/WO1999049788A1/en
Publication of WO1999049788A9 publication Critical patent/WO1999049788A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A61N7/02—Localised ultrasound hyperthermia
    • A61N7/022—Localised ultrasound hyperthermia intracavitary
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
    • A61B2017/00238—Type of minimally invasive operation
    • A61B2017/00274—Prostate operation, e.g. prostatectomy, turp, bhp treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
    • A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
    • A61B2018/00547—Prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B90/00—Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups A61B1/00 - A61B50/00, e.g. for luxation treatment or for protecting wound edges
    • A61B90/36—Image-producing devices or illumination devices not otherwise provided for
    • A61B90/37—Surgical systems with images on a monitor during operation
    • A61B2090/378—Surgical systems with images on a monitor during operation using ultrasound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A61N2007/0078—Ultrasound therapy with multiple treatment transducers

Definitions

  • This invention relates to techniques and apparatus for achieving ablation of tissue through the use of focussed ultrasound. It is disclosed in the context of a system and method for the ablation of prostate tissue in the treatment of, for example, benign prostate hyperplasia (BPH), but is believed to be applicable to the treatment of other conditions as well.
  • BPH benign prostate hyperplasia
  • U.S. Patents 5,409,006 and 5,443,069 also disclose the application of ultrasound for the treatment of BPH.
  • Several references disclose the treatment of BPH by electromagnetic radiation, for example, microwaves, applied transrectally, transurethrally or otherwise. Illustrative of these references are U.S. Patents: 5,330,518 and 5,480,417.
  • Other ultrasound applications for the treatment of disease are illustrated in, for example, U.S.
  • the disclosures of these references are incorporated herein by reference.
  • urologists are trained in the transurethral treatment of the prostate.
  • the present invention is disclosed in the context of transurethral treatment of the prostate.
  • a method for treating tissue includes orienting an ultrasound transducer at a first longitudinal orientation and a first angular orientation adjacent a treatment region, exciting the transducer to ablate tissue adjacent the first longitudinal orientation and the first angular orientation within the treatment region, orienting the transducer at the first longitudinal orientation and a second angular orientation adjacent the treatment region, exciting the transducer to ablate tissue adjacent the first longitudinal orientation and the second angular orientation within the treatment region, orienting the transducer at a second longitudinal orientation and the first angular orientation adjacent the treatment region, and exciting the transducer to ablate tissue adjacent the second longitudinal orientation and the first angular orientation within the treatment region.
  • a method of treating tissue comprises orienting an ultrasound transducer at a first longitudinal orientation and a first angular orientation adjacent the treatment region, exciting the transducer to ablate tissue adjacent the first longitudinal orientation and the first angular orientation within the treatment region, orienting the transducer at a second longitudinal orientation and a second angular orientation adjacent the treatment region, and exciting the transducer to ablate tissue adjacent the second longitudinal orientation and the second angular orientation within the treatment region.
  • orienting the transducer at a first longitudinal orientation and a first angular orientation includes positioning a catheter including a lumen adjacent the treatment region, maintaining substantially the position of the catheter adjacent the treatment region, and passing the transducer into the lumen so that the transducer is oriented adjacent the treatment region.
  • the method includes providing an indicator for indicating the longitudinal and angular orientation of the transducer.
  • the method includes providing a drive system for driving the transducer, providing the transducer and providing the drive system together including providing an ultrasound transducer and drive system having a variable focal length.
  • positioning a catheter adjacent the treatment region includes positioning a catheter including a balloon region adjacent the treatment region and filling the balloon region to maintain substantially the position of the catheter adjacent the treatment region.
  • an apparatus for treating tissue includes an ultrasound transducer for orienting at a first longitudinal orientation and a first angular orientation adjacent a treatment region, for orienting at the first longitudinal orientation and a second angular orientation adjacent the treatment region, and for orienting at a second longitudinal orientation and the first angular orientation adjacent the treatment region, and a drive system for exciting the transducer to ablate tissue adjacent the first longitudinal orientation and the first angular orientation within the treatment region, adjacent the first longitudinal orientation and the second angular orientation within the treatment region, and adjacent the second longitudinal orientation and the first angular orientation within the treatment region, respectively.
  • an apparatus for treating tissue includes an ultrasound transducer for orienting at a first longitudinal orientation and a first angular orientation adjacent a treatment region, and for orienting at a second longitudinal orientation and a second angular orientation adjacent the treatment region, and a drive system for exciting the transducer to ablate tissue adjacent the first longitudinal orientation and the first angular orientation within the treatment region, and adjacent the second longitudinal orientation and the second angular orientation within the treatment region.
  • the apparatus further includes a catheter including a lumen for positioning adjacent the treatment region, the lumen permitting passage of the transducer into the lumen so that the transducer can be oriented adjacent the treatment region.
  • the apparatus includes an indicator for indicating the longitudinal and angular orientation of the transducer.
  • the transducer and the drive system together include a transducer and drive system having a variable focal length.
  • the catheter includes a balloon region adjacent the treatment region, filling the balloon region maintaining substantially the position of the catheter.
  • Fig. 1 illustrates a fragmentary sectional side elevational view of an apparatus constructed according to the invention in place in the urethra and bladder of a patient being treated for BPH;
  • Fig. 2 illustrates a fragmentary perspective view taken generally along section lines 2-2 of Fig. 1;
  • Fig. 3 illustrates a transducer useful in performing methods according to the invention
  • Fig. 4 illustrates another treatment method which will produce a treatment lesion similar to the one illustrated in Fig. 2;
  • Fig. 5 illustrates a fragmentary sectional side elevational view of another apparatus constructed according to the invention.
  • Fig. 1 illustrates the lower portion of the bladder 20, bladder neck 22 and the upper portion of the urethra 24 of a patient suffering from BPH.
  • the prostate 26 which surrounds the upper portion of the urethra directly beneath the bladder 20 and around the bladder neck 22 becomes enlarged.
  • the symptoms of the disease are well known and discomforting. They generally result from the obstruction of the urethra by the enlarged prostate tissue. If not treated effectively, the disease can become complicated with devastating effect.
  • the classical surgical treatment is resection of some portion of the prostate transurethrally. While this method of treatment is frequently effective in the treatment of BPH, it is sometimes contraindicated by, for example, the patient's condition, reluctance of the patient based upon potential side effects, and so on.
  • a transurethral catheter 30 having a balloon end region 32 to aid in positioning the catheter 30 relative to the prostate 26 includes a lumen 34 in which is oriented a small ultrasound transducer 36 mounted on a support 38, such as a stiff wire.
  • Support 38 permits manipulation of the transducer 36 into the orientations necessary and/or desirable to treat the prostate 36 in the manner which will be outlined hereinafter.
  • some mechanism must be provided for satisfying the treating physician that the transducer 36 is properly oriented in the urethra 24 and prostate 26 prior to a given step in the treatment.
  • This may mean providing some sort of index or indicator 40 on the support 38 or on the transducer 36 which may be used in conjunction with some sort of visualization scheme, such as, for example, a transrectal ultrasound visualization system, and/or making the support 38 sufficiently torque-resistant and providing an indicator 42 on the outer end 44 of catheter 30 so that the treating physician can determine the orientation of the transducer 36.
  • Transducer 36 itself may be excited in a visualization mode in accordance with known techniques to aid in the process of orienting transducer 36 appropriately for the high intensity focussed ultrasound treatment that is to follow.
  • the transducer 36 is excited through appropriate electrical conductors 46 which extend through the lumen 34 from an ultrasound frequency generator 48.
  • Relatively high energy density ultrasound high enough that, once focussed by the transducer 36, it can either cause cavitation-induced injury and, ultimately, necrosis or elevate the temperature of the tissue sufficiently high, for example, 43 °C, for a sufficient time to cause necrosis, is transmitted by the transducer 36 into the tissue of the prostate 26, setting in motion the mechanisms of necrosis in the region of the transducer 36's focal point 52 and in the near field between the transducer 36 and the focal region in prostate 26.
  • the generator 48 must be capable of exciting the transducer 36 in the treatment mode with energies high enough to induce hyperthermia at the focal region when the transducer 36 is operated in the treatment mode.
  • energies in the range of hundreds of volts peak for times in the range of milliseconds ordinarily will achieve cavitation-induced necrosis in the focal zone.
  • lower exciting energies for longer periods of time, in the range of, for example, four to twenty seconds or so provide hyperthermia-induced necrosis.
  • different ultrasound-related phenomena can be employed by the treating physician to achieve tissue necrosis.
  • a transducer 36' (Fig. 3) with a variable focal depth, such as one of the general type illustrated in U.S. Patent 4,586,512, and supplied with ultrasound exciting signals related to each other as outlined in that patent, can be used to advantage to vary the focus of such a transducer 36' in such a treatment scheme. For example, the proper focal depth to treat any given depth of the prostate from the transducer's location in the urethra can be selected and the transducer 36' excited accordingly.
  • an appropriate frequency of excitation to provide the desired depth of ultrasound penetration and tissue treatment can be selected for any given treatment depth.
  • the treatment time can be established in accordance with known principles and guidelines. Guidelines can also be established for target, or desired, treatment lesion size and shape. One example of the flexibility of this method in the treatment of BPH can be appreciated by referring to Fig. 2.
  • the diseased prostate 26 is illustrated in perspective, and is sectioned at about the level at which the transducer 36 resides in the urethra 24.
  • a radially extending, or ray, lesion 60-1 is formed.
  • the tissue in this lesion begins to necrose.
  • the transducer support 38 is manipulated to turn transducer 36 so that its focal point now lies on a ray or radius extending at an angle of, for example, 5 c clockwise from vertical in Fig. 2.
  • Another treatment step just like the first is conducted, resulting in a second ray lesion 60-2.
  • tissue in this lesion begins to necrose. This process continues until a somewhat star- or bicycle wheel spokes-shaped composite lesion 60 is formed.
  • the support is then manipulated to move the transducer's focal point into a plane adjacent, but spaced slightly from, the plane of lesion 60.
  • the entire process is repeated, forming an adjacent and desirably overlapping star- or bicycle wheel spokes-shaped lesion 62.
  • the treating physician proceeds along the urethra in this manner, forming a number of adjacent and desirably overlapping lesions 60, 62, 64, 66, . . .. Necrosis of BPH tissue adjacent the urethra 24 results, eventually relieving the patient's symptoms.
  • the treating physician can also proceed along the length of the urethra 24 in the treatment zone first, and then reorient the transducer 36 angularly and move the transducer 36 along a path adjacent to the path followed during formation of the first lesion, repeating this process until a desired number of adjacent spoke-like lesions extending along the length of the desired treatment zone are formed.
  • a path is illustrated in Fig. 4.
  • Other procedures can also be followed to produce a composite lesion such as the one illustrated in Fig. 2, or any other desired configuration of lesion.
  • the transducer 36 can be a composite type, as illustrated by transducer 36' in Fig. 3.
  • multi-element transducer types such as two or more single element transducers side by side in lumen 34, can be employed with one element operated in a visualization mode and one in a treatment mode.
  • One such composite transducer is illustrated in Fig. 5. This composite transducer puts a treatment transducer 64 and a visualization transducer 66 side by side in the lumen 68 of a catheter 70. Additionally, this composite transducer adds another treatment transducer 72 which can be excited separately from treatment transducer 64 and/or visualization transducer 66. While the treatment transducers 36, 64 will effectively treat the main lobes of the prostate 74, a median lobe 76 of the prostate 74 of a BPH sufferer can grow inside the bladder neck 78.
  • This median lobe can be difficult to treat using transducers oriented as transducers 36, 64 are.
  • the transducer 72 oriented to face toward the remote end 74 of catheter 70 and at an angle ⁇ , 0° ⁇ ⁇ 90° to the longitudinal extent of catheter 70, permits treatment of the median lobe 76 of the prostate 74 to relieve the symptoms of BPH caused by enlargement of the median lobe 76 into the bladder neck 78.

Abstract

An apparatus for ablating tissue within a treatment region includes an ultrasound treatment transducer (36, 36') for orienting at a first longitudinal orientation and a first angular orientation (40, 42) within the treatment region (26), for orienting at the first longitudinal orientation and a second angular orientation (40, 42) within the treatment region, and for orienting at a second longitudinal orientation and the first angular orientation (40, 42) within the treatment region, and a drive system for exciting (via conductors (46)) the transducer (36, 36') to ablate tissue (60) oriented adjacent the first longitudinal orientation and the first angular orientation within the treatment region (26), adjacent the first longitudinal orientation and the second angular orientation within the treatment region (26), and adjacent the second longitudinal orientation and the first angular orientation within the treatment region (26), respectively.

Description

ABLATION SYSTEM
Background Of The Invention
This invention relates to techniques and apparatus for achieving ablation of tissue through the use of focussed ultrasound. It is disclosed in the context of a system and method for the ablation of prostate tissue in the treatment of, for example, benign prostate hyperplasia (BPH), but is believed to be applicable to the treatment of other conditions as well.
The use of transrectally applied high intensity focussed ultrasound in the treatment of diseases of the prostate is well documented. There are, for example, the disclosures of U.S. Patents 5, 117,832 and 5,676,692 and Fry, F. J. et al, "Ultrasound and Microbubbles: Their Generation, Detection and Potential Utilization in Tissue and Organ Therapy—Experimental," Ultrasound in Med. and Biol., vol. 21, no. 9, pp. 1227-1237, 1995 and Sanghvi, N. T., et al, "Noninvasive Surgery of Prostate Tissue by High-Intensity Focused Ultrasound," LEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, vol. 43, no. 6, pp. 1099-1110, Nov., 1996. U.S. Patents 5,409,006 and 5,443,069 also disclose the application of ultrasound for the treatment of BPH. Several references disclose the treatment of BPH by electromagnetic radiation, for example, microwaves, applied transrectally, transurethrally or otherwise. Illustrative of these references are U.S. Patents: 5,330,518 and 5,480,417. Other ultrasound applications for the treatment of disease are illustrated in, for example, U.S. Patent 5,247,935; 5,219,401; 5,215,680; 5,149,319; 5,054,470; 5,036,855; 4,955,365; 4,951,653; 4,858,613; 4,658,828; 4,586,512; and, 4,620,546. The disclosures of these references are incorporated herein by reference. Although the prostate can effectively be treated transrectally, urologists are trained in the transurethral treatment of the prostate. As a result, there has been some resistance to transrectal treatment of the prostate. The present invention is disclosed in the context of transurethral treatment of the prostate.
Disclosure of the Invention
According to one aspect of the invention, a method for treating tissue includes orienting an ultrasound transducer at a first longitudinal orientation and a first angular orientation adjacent a treatment region, exciting the transducer to ablate tissue adjacent the first longitudinal orientation and the first angular orientation within the treatment region, orienting the transducer at the first longitudinal orientation and a second angular orientation adjacent the treatment region, exciting the transducer to ablate tissue adjacent the first longitudinal orientation and the second angular orientation within the treatment region, orienting the transducer at a second longitudinal orientation and the first angular orientation adjacent the treatment region, and exciting the transducer to ablate tissue adjacent the second longitudinal orientation and the first angular orientation within the treatment region. According to another aspect of the invention, a method of treating tissue comprises orienting an ultrasound transducer at a first longitudinal orientation and a first angular orientation adjacent the treatment region, exciting the transducer to ablate tissue adjacent the first longitudinal orientation and the first angular orientation within the treatment region, orienting the transducer at a second longitudinal orientation and a second angular orientation adjacent the treatment region, and exciting the transducer to ablate tissue adjacent the second longitudinal orientation and the second angular orientation within the treatment region.
Illustratively according to these aspects of the invention, orienting the transducer at a first longitudinal orientation and a first angular orientation includes positioning a catheter including a lumen adjacent the treatment region, maintaining substantially the position of the catheter adjacent the treatment region, and passing the transducer into the lumen so that the transducer is oriented adjacent the treatment region.
Further illustratively according to these aspects of the invention, the method includes providing an indicator for indicating the longitudinal and angular orientation of the transducer.
Further illustratively according to these aspects of the invention, the method includes providing a drive system for driving the transducer, providing the transducer and providing the drive system together including providing an ultrasound transducer and drive system having a variable focal length. Additionally illustratively according to these aspects of the invention, positioning a catheter adjacent the treatment region includes positioning a catheter including a balloon region adjacent the treatment region and filling the balloon region to maintain substantially the position of the catheter adjacent the treatment region.
According to another aspect of the invention, an apparatus for treating tissue includes an ultrasound transducer for orienting at a first longitudinal orientation and a first angular orientation adjacent a treatment region, for orienting at the first longitudinal orientation and a second angular orientation adjacent the treatment region, and for orienting at a second longitudinal orientation and the first angular orientation adjacent the treatment region, and a drive system for exciting the transducer to ablate tissue adjacent the first longitudinal orientation and the first angular orientation within the treatment region, adjacent the first longitudinal orientation and the second angular orientation within the treatment region, and adjacent the second longitudinal orientation and the first angular orientation within the treatment region, respectively.
According to another aspect of the invention, an apparatus for treating tissue includes an ultrasound transducer for orienting at a first longitudinal orientation and a first angular orientation adjacent a treatment region, and for orienting at a second longitudinal orientation and a second angular orientation adjacent the treatment region, and a drive system for exciting the transducer to ablate tissue adjacent the first longitudinal orientation and the first angular orientation within the treatment region, and adjacent the second longitudinal orientation and the second angular orientation within the treatment region.
Illustratively according to these aspects of the invention, the apparatus further includes a catheter including a lumen for positioning adjacent the treatment region, the lumen permitting passage of the transducer into the lumen so that the transducer can be oriented adjacent the treatment region. Further illustratively according to these aspects of the invention, the apparatus includes an indicator for indicating the longitudinal and angular orientation of the transducer.
Additionally illustratively according to these aspects of the invention, the transducer and the drive system together include a transducer and drive system having a variable focal length. Illustratively according to these aspects of the invention, the catheter includes a balloon region adjacent the treatment region, filling the balloon region maintaining substantially the position of the catheter.
Brief Description Of The Drawings
The invention may best be understood by referring to the following detailed description of an illustrative embodiment of the invention and the accompanying drawings. In the drawings:
Fig. 1 illustrates a fragmentary sectional side elevational view of an apparatus constructed according to the invention in place in the urethra and bladder of a patient being treated for BPH;
Fig. 2 illustrates a fragmentary perspective view taken generally along section lines 2-2 of Fig. 1;
Fig. 3 illustrates a transducer useful in performing methods according to the invention;
Fig. 4 illustrates another treatment method which will produce a treatment lesion similar to the one illustrated in Fig. 2; and,
Fig. 5 illustrates a fragmentary sectional side elevational view of another apparatus constructed according to the invention.
Detailed Descriptions Of Illustrative Embodiments
Fig. 1 illustrates the lower portion of the bladder 20, bladder neck 22 and the upper portion of the urethra 24 of a patient suffering from BPH. The prostate 26 which surrounds the upper portion of the urethra directly beneath the bladder 20 and around the bladder neck 22 becomes enlarged. The symptoms of the disease are well known and discomforting. They generally result from the obstruction of the urethra by the enlarged prostate tissue. If not treated effectively, the disease can become complicated with devastating effect. The classical surgical treatment is resection of some portion of the prostate transurethrally. While this method of treatment is frequently effective in the treatment of BPH, it is sometimes contraindicated by, for example, the patient's condition, reluctance of the patient based upon potential side effects, and so on. According to the invention, a transurethral catheter 30 having a balloon end region 32 to aid in positioning the catheter 30 relative to the prostate 26 includes a lumen 34 in which is oriented a small ultrasound transducer 36 mounted on a support 38, such as a stiff wire. Support 38 permits manipulation of the transducer 36 into the orientations necessary and/or desirable to treat the prostate 36 in the manner which will be outlined hereinafter. At the same time however, some mechanism must be provided for satisfying the treating physician that the transducer 36 is properly oriented in the urethra 24 and prostate 26 prior to a given step in the treatment. This may mean providing some sort of index or indicator 40 on the support 38 or on the transducer 36 which may be used in conjunction with some sort of visualization scheme, such as, for example, a transrectal ultrasound visualization system, and/or making the support 38 sufficiently torque-resistant and providing an indicator 42 on the outer end 44 of catheter 30 so that the treating physician can determine the orientation of the transducer 36. Transducer 36 itself may be excited in a visualization mode in accordance with known techniques to aid in the process of orienting transducer 36 appropriately for the high intensity focussed ultrasound treatment that is to follow.
In any event, once the treating physician is satisfied of the positioning of the transducer 36, the transducer 36 is excited through appropriate electrical conductors 46 which extend through the lumen 34 from an ultrasound frequency generator 48. Relatively high energy density ultrasound, high enough that, once focussed by the transducer 36, it can either cause cavitation-induced injury and, ultimately, necrosis or elevate the temperature of the tissue sufficiently high, for example, 43 °C, for a sufficient time to cause necrosis, is transmitted by the transducer 36 into the tissue of the prostate 26, setting in motion the mechanisms of necrosis in the region of the transducer 36's focal point 52 and in the near field between the transducer 36 and the focal region in prostate 26. After necrosis begins, the necrotized tissue is resorbed into the body, relieving the symptoms of BPH experienced by the patient. The generator 48 must be capable of exciting the transducer 36 in the treatment mode with energies high enough to induce hyperthermia at the focal region when the transducer 36 is operated in the treatment mode. Energies in the range of hundreds of volts peak for times in the range of milliseconds ordinarily will achieve cavitation-induced necrosis in the focal zone. In the near field between the transducer 36 and the focal zone, lower exciting energies for longer periods of time, in the range of, for example, four to twenty seconds or so, provide hyperthermia-induced necrosis. Thus, different ultrasound-related phenomena can be employed by the treating physician to achieve tissue necrosis. Resorption will typically follow in due course. Using a transducer 36 which has a relatively short focal length increases the likelihood that all of the treated tissue can be constrained to the prostate. A transducer 36' (Fig. 3) with a variable focal depth, such as one of the general type illustrated in U.S. Patent 4,586,512, and supplied with ultrasound exciting signals related to each other as outlined in that patent, can be used to advantage to vary the focus of such a transducer 36' in such a treatment scheme. For example, the proper focal depth to treat any given depth of the prostate from the transducer's location in the urethra can be selected and the transducer 36' excited accordingly. Alternatively, or perhaps additionally, an appropriate frequency of excitation to provide the desired depth of ultrasound penetration and tissue treatment can be selected for any given treatment depth. The treatment time can be established in accordance with known principles and guidelines. Guidelines can also be established for target, or desired, treatment lesion size and shape. One example of the flexibility of this method in the treatment of BPH can be appreciated by referring to Fig. 2.
In Fig. 2, the diseased prostate 26 is illustrated in perspective, and is sectioned at about the level at which the transducer 36 resides in the urethra 24. After treatment of the prostate 26 with the transducer 36 oriented at a specific angle of, for example, 0°, corresponding to vertically upward in Fig. 2, a radially extending, or ray, lesion 60-1 is formed. The tissue in this lesion begins to necrose. The transducer support 38 is manipulated to turn transducer 36 so that its focal point now lies on a ray or radius extending at an angle of, for example, 5 c clockwise from vertical in Fig. 2. Another treatment step just like the first is conducted, resulting in a second ray lesion 60-2. The tissue in this lesion begins to necrose. This process continues until a somewhat star- or bicycle wheel spokes-shaped composite lesion 60 is formed. The support is then manipulated to move the transducer's focal point into a plane adjacent, but spaced slightly from, the plane of lesion 60. The entire process is repeated, forming an adjacent and desirably overlapping star- or bicycle wheel spokes-shaped lesion 62. The treating physician proceeds along the urethra in this manner, forming a number of adjacent and desirably overlapping lesions 60, 62, 64, 66, . . .. Necrosis of BPH tissue adjacent the urethra 24 results, eventually relieving the patient's symptoms.
Of course, the treating physician can also proceed along the length of the urethra 24 in the treatment zone first, and then reorient the transducer 36 angularly and move the transducer 36 along a path adjacent to the path followed during formation of the first lesion, repeating this process until a desired number of adjacent spoke-like lesions extending along the length of the desired treatment zone are formed. Such a path is illustrated in Fig. 4. Other procedures can also be followed to produce a composite lesion such as the one illustrated in Fig. 2, or any other desired configuration of lesion. The transducer 36 can be a composite type, as illustrated by transducer 36' in Fig. 3. Other multi-element transducer types, such as two or more single element transducers side by side in lumen 34, can be employed with one element operated in a visualization mode and one in a treatment mode. One such composite transducer is illustrated in Fig. 5. This composite transducer puts a treatment transducer 64 and a visualization transducer 66 side by side in the lumen 68 of a catheter 70. Additionally, this composite transducer adds another treatment transducer 72 which can be excited separately from treatment transducer 64 and/or visualization transducer 66. While the treatment transducers 36, 64 will effectively treat the main lobes of the prostate 74, a median lobe 76 of the prostate 74 of a BPH sufferer can grow inside the bladder neck 78. This median lobe can be difficult to treat using transducers oriented as transducers 36, 64 are. The transducer 72 oriented to face toward the remote end 74 of catheter 70 and at an angle α, 0° < < 90° to the longitudinal extent of catheter 70, permits treatment of the median lobe 76 of the prostate 74 to relieve the symptoms of BPH caused by enlargement of the median lobe 76 into the bladder neck 78.

Claims

Claims:
1. A method of treating tissue comprising orienting an ultrasound transducer at a first longitudinal orientation and a first angular orientation adjacent the treatment region, exciting the transducer to ablate tissue adjacent the first longitudinal orientation and the first angular orientation within the treatment region, orienting the transducer at a second longitudinal orientation and the first angular orientation adjacent the treatment region, exciting the transducer to ablate tissue adjacent the second longitudinal orientation and the first angular orientation within the treatment region, orienting the transducer at the first longitudinal orientation and a second angular orientation adjacent the treatment region, and exciting the transducer to ablate tissue adjacent the first longitudinal orientation and the second angular orientation within the treatment region.
2. A method of treating tissue comprising orienting an ultrasound transducer at a first longitudinal orientation and a first angular orientation adjacent the treatment region, exciting the transducer to ablate tissue adjacent the first longitudinal orientation and the first angular orientation within the treatment region, orienting the transducer at a second longitudinal orientation and a second angular orientation adjacent the treatment region, and exciting the transducer to ablate tissue adjacent the second longitudinal orientation and the second angular orientation within the treatment region.
3. The method of claim 1 or 2 wherein orienting the transducer at a first longitudinal orientation and a first angular orientation includes positioning a catheter including a lumen adjacent the treatment region, substantially maintaining the position of the catheter adjacent the treatment region, and passing the transducer into the lumen so that the transducer is oriented adjacent the treatment region.
4. The method of claim 3 further includinging providing an indicator for indicating the longitudinal and angular orientation of the transducer.
5. The method of claim 1 or 2 further including providing an indicator for indicating the longitudinal and angular orientation of the transducer.
6. The method of claim 5 further including providing a drive system for driving the transducer, providing the transducer and providing the drive system including providing an ultrasound transducer and drive system having a variable focal length.
7. The method of claim 4 further including providing a drive system for driving the transducer, providing the transducer and providing the drive system including providing a transducer and drive system having a variable focal length.
8. The method of claim 3 further including providing a drive system for driving the transducer, providing the transducer and providing the drive system including providing a transducer and drive system having a variable focal length.
9. The method of claim 1 or 2 further including providing a drive system for driving the transducer, providing the transducer and providing the drive system including providing a transducer and drive system having a variable focal length.
10. The method of claim 3 wherein positioning a catheter adjacent the treatment region includes positioning a catheter including a balloon region adjacent the treatment region and filling the balloon region to maintain substantially the position of the catheter.
11. The method of claim 4 wherein positioning a catheter adjacent the treatment region includes positioning a catheter including a balloon region adjacent the treatment region and filling the balloon region to maintain substantially the position of the catheter.
12. The method of claim 7 wherein positioning a catheter adjacent the treatment region includes positioning a catheter including a balloon region adjacent the treatment region and filling the balloon region to maintain substantially the position of the catheter.
13. The method of claim 8 wherein positioning a catheter adjacent the treatment region includes positioning a catheter including a balloon region adjacent the treatment region and filling the balloon region to maintain substantially the position of the catheter.
14. Apparatus for treating tissue including an ultrasound transducer for orienting at a first longitudinal orientation and a first angular orientation adjacent the treatment region, at a second longitudinal orientation and the first angular orientation adjacent the treatment region, and at the first longitudinal orientation and a second angular orientation adjacent the treatment region, and a drive system for exciting the transducer to ablate tissue oriented adjacent the first longitudinal orientation and the first angular orientation within the treatment region, adjacent the second longitudinal orientation and the first angular orientation within the treatment region, and adjacent the first longitudinal orientation and the second angular orientation within the treatment region, respectively.
15. Apparatus for treating tissue including an ultrasound transducer for orienting at a first longitudinal orientation and a first angular orientation adjacent the treatment region, and at a second longitudinal orientation and a second angular orientation adjacent the treatment region, and a drive system for exciting the transducer to ablate tissue oriented adjacent the first longitudinal orientation and the first angular orientation within the treatment region, and adjacent the second longitudinal orientation and the second angular orientation within the treatment region, respectively.
16. The apparatus of claim 14 or 15 further including a catheter including a lumen for positioning adjacent the treatment region, the lumen permitting passage of the transducer into the lumen so that the transducer can be oriented adjacent the treatment region.
17. The apparatus of claim 16 further including an indicator for indicating the longitudinal and angular orientation of the transducer adjacent the treatment region.
18. The apparatus of claim 14 or 15 further including an indicator for indicating the longitudinal and angular orientation of the transducer adjacent the treatment region.
19. The apparatus of claim 18 wherein the transducer and the drive system together include a transducer and drive system having a variable focal length.
20. The apparatus of claim 17 wherein the transducer and the drive system together include a transducer and drive system having a variable focal length.
21. The apparatus of claim 16 wherein the transducer and the drive system together include a transducer and drive system having a variable focal length.
22. The apparatus of claim 14 or 15 wherein the transducer and the drive system together include a transducer and drive system having a variable focal length.
23. The apparatus of claim 16 wherein the catheter includes a balloon region adjacent the treatment region, filling the balloon region maintaining substantially the position of the catheter.
24. The apparatus of claim 17 wherein the catheter includes a balloon region adjacent the treatment region, filling the balloon region maintaining substantially the position of the catheter.
25. The apparatus of claim 20 wherein the catheter includes a balloon region adjacent the treatment region, filling the balloon region maintaining substantially the position of the catheter.
26. The apparatus of claim 21 wherein the catheter includes a balloon region adjacent the treatment region, filling the balloon region maintaining substantially the position of the catheter.
PCT/US1999/006974 1998-03-30 1999-03-30 Ablation system WO1999049788A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US09/647,317 US6685640B1 (en) 1998-03-30 1999-03-30 Ablation system

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7994598P 1998-03-30 1998-03-30
US60/079,945 1998-03-30

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09/647,317 A-371-Of-International US6685640B1 (en) 1998-03-30 1999-03-30 Ablation system
US10/667,533 Division US20040059266A1 (en) 1998-03-30 2003-09-22 Ablation system

Publications (2)

Publication Number Publication Date
WO1999049788A1 true WO1999049788A1 (en) 1999-10-07
WO1999049788A9 WO1999049788A9 (en) 2000-02-17

Family

ID=22153827

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/006974 WO1999049788A1 (en) 1998-03-30 1999-03-30 Ablation system

Country Status (1)

Country Link
WO (1) WO1999049788A1 (en)

Cited By (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311701B2 (en) * 2003-06-10 2007-12-25 Cierra, Inc. Methods and apparatus for non-invasively treating atrial fibrillation using high intensity focused ultrasound
US7393325B2 (en) 2004-09-16 2008-07-01 Guided Therapy Systems, L.L.C. Method and system for ultrasound treatment with a multi-directional transducer
US9039619B2 (en) 2004-10-06 2015-05-26 Guided Therapy Systems, L.L.C. Methods for treating skin laxity
US9039617B2 (en) 2009-11-24 2015-05-26 Guided Therapy Systems, Llc Methods and systems for generating thermal bubbles for improved ultrasound imaging and therapy
US9055959B2 (en) 1999-07-19 2015-06-16 St. Jude Medical, Atrial Fibrillation Division, Inc. Methods and devices for ablation
US9089538B2 (en) 2010-04-27 2015-07-28 Zealand Pharma A/S Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
US9694212B2 (en) 2004-10-06 2017-07-04 Guided Therapy Systems, Llc Method and system for ultrasound treatment of skin
US9700340B2 (en) 2004-10-06 2017-07-11 Guided Therapy Systems, Llc System and method for ultra-high frequency ultrasound treatment
US9707412B2 (en) 2004-10-06 2017-07-18 Guided Therapy Systems, Llc System and method for fat and cellulite reduction
US9713731B2 (en) 2004-10-06 2017-07-25 Guided Therapy Systems, Llc Energy based fat reduction
US9802063B2 (en) 2012-09-21 2017-10-31 Guided Therapy Systems, Llc Reflective ultrasound technology for dermatological treatments
US9827449B2 (en) 2004-10-06 2017-11-28 Guided Therapy Systems, L.L.C. Systems for treating skin laxity
US9861706B2 (en) 2011-11-03 2018-01-09 Zealand Pharma A/S GLP-1 receptor agonist peptide gastrin conjugates
US9895560B2 (en) 2004-09-24 2018-02-20 Guided Therapy Systems, Llc Methods for rejuvenating skin by heating tissue for cosmetic treatment of the face and body
US9907535B2 (en) 2000-12-28 2018-03-06 Ardent Sound, Inc. Visual imaging system for ultrasonic probe
US9975939B2 (en) 2012-09-17 2018-05-22 Zealand Pharma A/S Glucagon analogues
US9974982B2 (en) 2004-10-06 2018-05-22 Guided Therapy Systems, Llc System and method for noninvasive skin tightening
US10039938B2 (en) 2004-09-16 2018-08-07 Guided Therapy Systems, Llc System and method for variable depth ultrasound treatment
US10046181B2 (en) 2004-10-06 2018-08-14 Guided Therapy Systems, Llc Energy based hyperhidrosis treatment
US10058380B2 (en) 2007-10-05 2018-08-28 Maquet Cordiovascular Llc Devices and methods for minimally-invasive surgical procedures
US10093713B2 (en) 2013-11-06 2018-10-09 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
US10131702B2 (en) 2013-11-06 2018-11-20 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
US10183182B2 (en) 2010-08-02 2019-01-22 Guided Therapy Systems, Llc Methods and systems for treating plantar fascia
US10253078B2 (en) 2014-10-29 2019-04-09 Zealand Pharma A/S GIP agonist compounds and methods
US10293188B2 (en) 2005-07-08 2019-05-21 Focus Surgery, Inc. Method and apparatus for the treatment of tissue
US10336802B2 (en) 2015-04-16 2019-07-02 Zealand Pharma A/S Acylated glucagon analogue
US10420960B2 (en) 2013-03-08 2019-09-24 Ulthera, Inc. Devices and methods for multi-focus ultrasound therapy
US10457714B2 (en) 2013-10-17 2019-10-29 Zealand Pharma A/S Acylated glucagon analogues
US10537304B2 (en) 2008-06-06 2020-01-21 Ulthera, Inc. Hand wand for ultrasonic cosmetic treatment and imaging
US10561862B2 (en) 2013-03-15 2020-02-18 Guided Therapy Systems, Llc Ultrasound treatment device and methods of use
US10603521B2 (en) 2014-04-18 2020-03-31 Ulthera, Inc. Band transducer ultrasound therapy
US10864385B2 (en) 2004-09-24 2020-12-15 Guided Therapy Systems, Llc Rejuvenating skin by heating tissue for cosmetic treatment of the face and body
US10905745B2 (en) 2016-12-09 2021-02-02 Zealand Pharma A/S Acylated GLP-1/GLP-2 dual agonists
US11034747B2 (en) 2013-10-17 2021-06-15 Zealand Pharma A/S Glucagon analogues and methods of use
US11207548B2 (en) 2004-10-07 2021-12-28 Guided Therapy Systems, L.L.C. Ultrasound probe for treating skin laxity
US11224895B2 (en) 2016-01-18 2022-01-18 Ulthera, Inc. Compact ultrasound device having annular ultrasound array peripherally electrically connected to flexible printed circuit board and method of assembly thereof
US11235179B2 (en) 2004-10-06 2022-02-01 Guided Therapy Systems, Llc Energy based skin gland treatment
US11241218B2 (en) 2016-08-16 2022-02-08 Ulthera, Inc. Systems and methods for cosmetic ultrasound treatment of skin
US11338156B2 (en) 2004-10-06 2022-05-24 Guided Therapy Systems, Llc Noninvasive tissue tightening system
US11717661B2 (en) 2007-05-07 2023-08-08 Guided Therapy Systems, Llc Methods and systems for ultrasound assisted delivery of a medicant to tissue
US11724133B2 (en) 2004-10-07 2023-08-15 Guided Therapy Systems, Llc Ultrasound probe for treatment of skin
US11795204B2 (en) 2012-07-23 2023-10-24 Zealand Pharma A/S Glucagon analogues
US11883688B2 (en) 2004-10-06 2024-01-30 Guided Therapy Systems, Llc Energy based fat reduction
US11944849B2 (en) 2018-02-20 2024-04-02 Ulthera, Inc. Systems and methods for combined cosmetic treatment of cellulite with ultrasound

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6050943A (en) 1997-10-14 2000-04-18 Guided Therapy Systems, Inc. Imaging, therapy, and temperature monitoring ultrasonic system
US9011336B2 (en) 2004-09-16 2015-04-21 Guided Therapy Systems, Llc Method and system for combined energy therapy profile
EP2279696A3 (en) 2004-10-06 2014-02-26 Guided Therapy Systems, L.L.C. Method and system for non-invasive mastopexy
US7571336B2 (en) 2005-04-25 2009-08-04 Guided Therapy Systems, L.L.C. Method and system for enhancing safety with medical peripheral device by monitoring if host computer is AC powered
US8932208B2 (en) 2005-05-26 2015-01-13 Maquet Cardiovascular Llc Apparatus and methods for performing minimally-invasive surgical procedures
US9566454B2 (en) 2006-09-18 2017-02-14 Guided Therapy Systems, Llc Method and sysem for non-ablative acne treatment and prevention
US9241683B2 (en) 2006-10-04 2016-01-26 Ardent Sound Inc. Ultrasound system and method for imaging and/or measuring displacement of moving tissue and fluid
TWI526233B (en) 2007-05-07 2016-03-21 指導治療系統股份有限公司 Methods and systems for modulating medicants using acoustic energy
US9504446B2 (en) 2010-08-02 2016-11-29 Guided Therapy Systems, Llc Systems and methods for coupling an ultrasound source to tissue
US8857438B2 (en) 2010-11-08 2014-10-14 Ulthera, Inc. Devices and methods for acoustic shielding
US9452302B2 (en) 2011-07-10 2016-09-27 Guided Therapy Systems, Llc Systems and methods for accelerating healing of implanted material and/or native tissue
KR20140047709A (en) 2011-07-11 2014-04-22 가이디드 테라피 시스템스, 엘.엘.씨. Systems and methods for coupling an ultrasound source to tissue
US9263663B2 (en) 2012-04-13 2016-02-16 Ardent Sound, Inc. Method of making thick film transducer arrays

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4586512A (en) * 1981-06-26 1986-05-06 Thomson-Csf Device for localized heating of biological tissues
US5080102A (en) * 1983-12-14 1992-01-14 Edap International, S.A. Examining, localizing and treatment with ultrasound
US5149319A (en) * 1990-09-11 1992-09-22 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids
US5295484A (en) * 1992-05-19 1994-03-22 Arizona Board Of Regents For And On Behalf Of The University Of Arizona Apparatus and method for intra-cardiac ablation of arrhythmias
US5676692A (en) * 1996-03-28 1997-10-14 Indianapolis Center For Advanced Research, Inc. Focussed ultrasound tissue treatment method
US5840031A (en) * 1993-07-01 1998-11-24 Boston Scientific Corporation Catheters for imaging, sensing electrical potentials and ablating tissue

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4586512A (en) * 1981-06-26 1986-05-06 Thomson-Csf Device for localized heating of biological tissues
US5080102A (en) * 1983-12-14 1992-01-14 Edap International, S.A. Examining, localizing and treatment with ultrasound
US5149319A (en) * 1990-09-11 1992-09-22 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids
US5295484A (en) * 1992-05-19 1994-03-22 Arizona Board Of Regents For And On Behalf Of The University Of Arizona Apparatus and method for intra-cardiac ablation of arrhythmias
US5840031A (en) * 1993-07-01 1998-11-24 Boston Scientific Corporation Catheters for imaging, sensing electrical potentials and ablating tissue
US5676692A (en) * 1996-03-28 1997-10-14 Indianapolis Center For Advanced Research, Inc. Focussed ultrasound tissue treatment method

Cited By (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9055959B2 (en) 1999-07-19 2015-06-16 St. Jude Medical, Atrial Fibrillation Division, Inc. Methods and devices for ablation
US9907535B2 (en) 2000-12-28 2018-03-06 Ardent Sound, Inc. Visual imaging system for ultrasonic probe
US7311701B2 (en) * 2003-06-10 2007-12-25 Cierra, Inc. Methods and apparatus for non-invasively treating atrial fibrillation using high intensity focused ultrasound
US7393325B2 (en) 2004-09-16 2008-07-01 Guided Therapy Systems, L.L.C. Method and system for ultrasound treatment with a multi-directional transducer
US8057389B2 (en) 2004-09-16 2011-11-15 Guided Therapy Systems, Llc Method and system for ultrasound treatment with a multi-directional transducer
US10039938B2 (en) 2004-09-16 2018-08-07 Guided Therapy Systems, Llc System and method for variable depth ultrasound treatment
US9895560B2 (en) 2004-09-24 2018-02-20 Guided Therapy Systems, Llc Methods for rejuvenating skin by heating tissue for cosmetic treatment of the face and body
US10864385B2 (en) 2004-09-24 2020-12-15 Guided Therapy Systems, Llc Rejuvenating skin by heating tissue for cosmetic treatment of the face and body
US10328289B2 (en) 2004-09-24 2019-06-25 Guided Therapy Systems, Llc Rejuvenating skin by heating tissue for cosmetic treatment of the face and body
US10532230B2 (en) 2004-10-06 2020-01-14 Guided Therapy Systems, Llc Methods for face and neck lifts
US11207547B2 (en) 2004-10-06 2021-12-28 Guided Therapy Systems, Llc Probe for ultrasound tissue treatment
US9707412B2 (en) 2004-10-06 2017-07-18 Guided Therapy Systems, Llc System and method for fat and cellulite reduction
US9713731B2 (en) 2004-10-06 2017-07-25 Guided Therapy Systems, Llc Energy based fat reduction
US11883688B2 (en) 2004-10-06 2024-01-30 Guided Therapy Systems, Llc Energy based fat reduction
US10603519B2 (en) 2004-10-06 2020-03-31 Guided Therapy Systems, Llc Energy based fat reduction
US9827450B2 (en) 2004-10-06 2017-11-28 Guided Therapy Systems, L.L.C. System and method for fat and cellulite reduction
US9833640B2 (en) 2004-10-06 2017-12-05 Guided Therapy Systems, L.L.C. Method and system for ultrasound treatment of skin
US9833639B2 (en) 2004-10-06 2017-12-05 Guided Therapy Systems, L.L.C. Energy based fat reduction
US11717707B2 (en) 2004-10-06 2023-08-08 Guided Therapy Systems, Llc System and method for noninvasive skin tightening
US9694212B2 (en) 2004-10-06 2017-07-04 Guided Therapy Systems, Llc Method and system for ultrasound treatment of skin
US9694211B2 (en) 2004-10-06 2017-07-04 Guided Therapy Systems, L.L.C. Systems for treating skin laxity
US11697033B2 (en) 2004-10-06 2023-07-11 Guided Therapy Systems, Llc Methods for lifting skin tissue
US9974982B2 (en) 2004-10-06 2018-05-22 Guided Therapy Systems, Llc System and method for noninvasive skin tightening
US10010721B2 (en) 2004-10-06 2018-07-03 Guided Therapy Systems, L.L.C. Energy based fat reduction
US10010726B2 (en) 2004-10-06 2018-07-03 Guided Therapy Systems, Llc Ultrasound probe for treatment of skin
US10010724B2 (en) 2004-10-06 2018-07-03 Guided Therapy Systems, L.L.C. Ultrasound probe for treating skin laxity
US10010725B2 (en) 2004-10-06 2018-07-03 Guided Therapy Systems, Llc Ultrasound probe for fat and cellulite reduction
US11400319B2 (en) 2004-10-06 2022-08-02 Guided Therapy Systems, Llc Methods for lifting skin tissue
US10046182B2 (en) 2004-10-06 2018-08-14 Guided Therapy Systems, Llc Methods for face and neck lifts
US10046181B2 (en) 2004-10-06 2018-08-14 Guided Therapy Systems, Llc Energy based hyperhidrosis treatment
US11338156B2 (en) 2004-10-06 2022-05-24 Guided Therapy Systems, Llc Noninvasive tissue tightening system
US11235179B2 (en) 2004-10-06 2022-02-01 Guided Therapy Systems, Llc Energy based skin gland treatment
US11235180B2 (en) 2004-10-06 2022-02-01 Guided Therapy Systems, Llc System and method for noninvasive skin tightening
US9700340B2 (en) 2004-10-06 2017-07-11 Guided Therapy Systems, Llc System and method for ultra-high frequency ultrasound treatment
US10238894B2 (en) 2004-10-06 2019-03-26 Guided Therapy Systems, L.L.C. Energy based fat reduction
US10245450B2 (en) 2004-10-06 2019-04-02 Guided Therapy Systems, Llc Ultrasound probe for fat and cellulite reduction
US11179580B2 (en) 2004-10-06 2021-11-23 Guided Therapy Systems, Llc Energy based fat reduction
US10252086B2 (en) 2004-10-06 2019-04-09 Guided Therapy Systems, Llc Ultrasound probe for treatment of skin
US11167155B2 (en) 2004-10-06 2021-11-09 Guided Therapy Systems, Llc Ultrasound probe for treatment of skin
US10960236B2 (en) 2004-10-06 2021-03-30 Guided Therapy Systems, Llc System and method for noninvasive skin tightening
US10888718B2 (en) 2004-10-06 2021-01-12 Guided Therapy Systems, L.L.C. Ultrasound probe for treating skin laxity
US10888716B2 (en) 2004-10-06 2021-01-12 Guided Therapy Systems, Llc Energy based fat reduction
US10888717B2 (en) 2004-10-06 2021-01-12 Guided Therapy Systems, Llc Probe for ultrasound tissue treatment
US9039619B2 (en) 2004-10-06 2015-05-26 Guided Therapy Systems, L.L.C. Methods for treating skin laxity
US10610705B2 (en) 2004-10-06 2020-04-07 Guided Therapy Systems, L.L.C. Ultrasound probe for treating skin laxity
US10610706B2 (en) 2004-10-06 2020-04-07 Guided Therapy Systems, Llc Ultrasound probe for treatment of skin
US10525288B2 (en) 2004-10-06 2020-01-07 Guided Therapy Systems, Llc System and method for noninvasive skin tightening
US10603523B2 (en) 2004-10-06 2020-03-31 Guided Therapy Systems, Llc Ultrasound probe for tissue treatment
US9827449B2 (en) 2004-10-06 2017-11-28 Guided Therapy Systems, L.L.C. Systems for treating skin laxity
US10265550B2 (en) 2004-10-06 2019-04-23 Guided Therapy Systems, L.L.C. Ultrasound probe for treating skin laxity
US11207548B2 (en) 2004-10-07 2021-12-28 Guided Therapy Systems, L.L.C. Ultrasound probe for treating skin laxity
US11724133B2 (en) 2004-10-07 2023-08-15 Guided Therapy Systems, Llc Ultrasound probe for treatment of skin
US10293188B2 (en) 2005-07-08 2019-05-21 Focus Surgery, Inc. Method and apparatus for the treatment of tissue
US11717661B2 (en) 2007-05-07 2023-08-08 Guided Therapy Systems, Llc Methods and systems for ultrasound assisted delivery of a medicant to tissue
US10993766B2 (en) 2007-10-05 2021-05-04 Maquet Cardiovascular Llc Devices and methods for minimally-invasive surgical procedures
US10058380B2 (en) 2007-10-05 2018-08-28 Maquet Cordiovascular Llc Devices and methods for minimally-invasive surgical procedures
US10537304B2 (en) 2008-06-06 2020-01-21 Ulthera, Inc. Hand wand for ultrasonic cosmetic treatment and imaging
US11723622B2 (en) 2008-06-06 2023-08-15 Ulthera, Inc. Systems for ultrasound treatment
US11123039B2 (en) 2008-06-06 2021-09-21 Ulthera, Inc. System and method for ultrasound treatment
US9039617B2 (en) 2009-11-24 2015-05-26 Guided Therapy Systems, Llc Methods and systems for generating thermal bubbles for improved ultrasound imaging and therapy
US9649362B2 (en) 2010-04-27 2017-05-16 Zealand Pharma A/S Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
US9089538B2 (en) 2010-04-27 2015-07-28 Zealand Pharma A/S Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
US10406207B2 (en) 2010-04-27 2019-09-10 Zealand Pharma A/S Peptide conjugates of GLP-1 receptor agonists and gastrin and their use
US10183182B2 (en) 2010-08-02 2019-01-22 Guided Therapy Systems, Llc Methods and systems for treating plantar fascia
US9861706B2 (en) 2011-11-03 2018-01-09 Zealand Pharma A/S GLP-1 receptor agonist peptide gastrin conjugates
US11795204B2 (en) 2012-07-23 2023-10-24 Zealand Pharma A/S Glucagon analogues
US9975939B2 (en) 2012-09-17 2018-05-22 Zealand Pharma A/S Glucagon analogues
US10253081B2 (en) 2012-09-17 2019-04-09 Zealand Pharma A/S Glucagon analogues
US9802063B2 (en) 2012-09-21 2017-10-31 Guided Therapy Systems, Llc Reflective ultrasound technology for dermatological treatments
US10420960B2 (en) 2013-03-08 2019-09-24 Ulthera, Inc. Devices and methods for multi-focus ultrasound therapy
US11517772B2 (en) 2013-03-08 2022-12-06 Ulthera, Inc. Devices and methods for multi-focus ultrasound therapy
US10561862B2 (en) 2013-03-15 2020-02-18 Guided Therapy Systems, Llc Ultrasound treatment device and methods of use
US11091528B2 (en) 2013-10-17 2021-08-17 Zealand Pharma A/S Acylated glucagon analogues
US11884713B2 (en) 2013-10-17 2024-01-30 Zealand Pharma A/S Acylated glucagon analogues
US11034747B2 (en) 2013-10-17 2021-06-15 Zealand Pharma A/S Glucagon analogues and methods of use
US10457714B2 (en) 2013-10-17 2019-10-29 Zealand Pharma A/S Acylated glucagon analogues
US10131702B2 (en) 2013-11-06 2018-11-20 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
US11111285B2 (en) 2013-11-06 2021-09-07 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
US10093713B2 (en) 2013-11-06 2018-10-09 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
US11008375B2 (en) 2013-11-06 2021-05-18 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
US11351401B2 (en) 2014-04-18 2022-06-07 Ulthera, Inc. Band transducer ultrasound therapy
US10603521B2 (en) 2014-04-18 2020-03-31 Ulthera, Inc. Band transducer ultrasound therapy
US11001619B2 (en) 2014-10-29 2021-05-11 Zealand Pharma A/S GIP agonist compounds and methods
US10253078B2 (en) 2014-10-29 2019-04-09 Zealand Pharma A/S GIP agonist compounds and methods
US11814417B2 (en) 2014-10-29 2023-11-14 Zealand Pharma A/S GIP agonist compounds and methods
US11274136B2 (en) 2015-04-16 2022-03-15 Zealand Pharma A/S Acylated glucagon analogue
US10336802B2 (en) 2015-04-16 2019-07-02 Zealand Pharma A/S Acylated glucagon analogue
US11224895B2 (en) 2016-01-18 2022-01-18 Ulthera, Inc. Compact ultrasound device having annular ultrasound array peripherally electrically connected to flexible printed circuit board and method of assembly thereof
US11241218B2 (en) 2016-08-16 2022-02-08 Ulthera, Inc. Systems and methods for cosmetic ultrasound treatment of skin
US10905745B2 (en) 2016-12-09 2021-02-02 Zealand Pharma A/S Acylated GLP-1/GLP-2 dual agonists
US11395847B2 (en) 2016-12-09 2022-07-26 Zealand Pharma A/S Acylated GLP-1/GLP-2 dual agonists
US11944849B2 (en) 2018-02-20 2024-04-02 Ulthera, Inc. Systems and methods for combined cosmetic treatment of cellulite with ultrasound

Also Published As

Publication number Publication date
WO1999049788A9 (en) 2000-02-17

Similar Documents

Publication Publication Date Title
US6685640B1 (en) Ablation system
WO1999049788A1 (en) Ablation system
US20200170702A1 (en) Ablation device with optimized input power profile and method of using the same
US8298162B2 (en) Skin and adipose tissue treatment by nonfocalized opposing side shock waves
Ter Haar High intensity focused ultrasound for the treatment of tumors
US6368292B1 (en) Method for using acoustic shock waves in the treatment of medical conditions
US6672312B2 (en) Pulmonary vein ablation with myocardial tissue locating
US7806839B2 (en) System and method for ultrasound therapy using grating lobes
JP5768056B2 (en) Method and apparatus for treating hypertension by percutaneous ultrasound renal nerve removal
CN100553714C (en) Use the medical apparatus and instruments of near-infrared LED treatment prostatosis
KR100233352B1 (en) Apparatus and method for transurethral focussed ultrasound therapy
US8197409B2 (en) Ultrasound guided high intensity focused ultrasound treatment of nerves
US5391197A (en) Ultrasound thermotherapy probe
US5207672A (en) Instrument and method for intraluminally relieving stenosis
JP4902105B2 (en) Externally supplied high-intensity focused ultrasound (HIFU) for pulmonary vein separation
US4905672A (en) Thromboses formation by means of shock waves
US5713831A (en) Method and apparatus for arterial reperfusion through noninvasive ultrasonic action
CN1798591B (en) Ultrasound probe having a central opening
JPH07184907A (en) Ultrasonic treating device
US20050234438A1 (en) Ultrasound medical treatment system and method
WO2000049952A1 (en) Method of using focused pressure fronts in myocardial revascularization
JP2003523794A (en) Thrombus disintegration system and method for treating seizures by intracranial ultrasound irradiation
Frizzell et al. Sparse random ultrasound array for focal surgery
US20090082703A1 (en) Method and apparatus for the treatment of tendon abnormalities
Lee Design, development, and evaluation of focused ultrasound arrays for transesophageal cardiac ablations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: C2

Designated state(s): CA JP US

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 1/2-2/2, DRAWINGS, REPLACED BY NEW PAGES 1/2-2/2; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 09647317

Country of ref document: US

122 Ep: pct application non-entry in european phase